Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Acquisition target Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year-over-year, with gross profit margin expanding 190 basis points to 67.9%. Global thrombectomy revenue increased 12.5% to $259.0 million, while embolization and access revenue grew 20.0% to $131.1 million.
Key figures
- Eps
- 0.88
- Revenue
- $390.0 million
- Revenue Yoy
- 14.9%
- Net income
- $34.8 million
- Gross margin
- 67.9%
- Operating income
- $41.0 million
- Embolization revenue
- $131.1 million
- Thrombectomy revenue
- $259.0 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.